Trump's Controversial Drug Pricing Plan Faces Backlash

President Donald Trump's plan to overhaul the pricing model for certain medications is generating substantial controversy even before the signing of his proposed executive order. Set to be signed on Monday, the order aims to reduce drug costs by tying Medicare-covered medication prices to those of the lowest-paying countries.

The commitment has been met with backlash from pharmaceutical leaders, who argue that the policy could hinder investments in drug development. Stephen J. Ubl, PhRMA's CEO, warned that the initiative might force increased reliance on international sources like China for new medications.

The executive order is expected to apply specifically to drugs under Medicare Part B, impacting only a select range of treatments. Despite Trump's claims of significant taxpayer savings, the benefits might remain limited, affecting primarily government expenses rather than individual patient costs.

(With inputs from agencies.)